Anika Therapeutics, Inc. (NASDAQ: ANIK) is a Healthcare company (Medical - Specialties) with a market capitalization of $172M. The Maz Rating grades it against the other companies in its sector.
Anika Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $12.85, Anika Therapeutics, Inc. trades at 1.4x sales and 1.2x book value, with an EV/EBITDA of 29.5. Over the last twelve months it generated about $124M of revenue and a net loss of $2M. It runs a gross margin of 63.4%, an operating margin of -2.1% and a net margin of -1.4%. It shows return on equity of -1.3%, return on invested capital of -0.4% and a free cash flow yield of 1.3%. On the balance sheet: a debt-to-equity ratio of 0.18 and a current ratio of 3.86. Over the past 52 weeks the share price ranged from $9.01 to $22.88, with a beta of 0.21.
Anika Therapeutics, Inc. does not currently pay a dividend.
7 Wall Street analyst ratings cover the stock: 4 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.